A Multicentre Observational Cohort Study to Compare Short Term and Midterm Outcomes after Fenestrated Endovascular Aortic Repair and Open Surgical Repair in Juxtarenal and Pararenal Aortic Aneurysm: The FEORA Study.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 42385842.
- Also identified by DOI 10.1016/j.ejvs.2026.06.014.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This multicentre, retrospective cohort study aimed compare fenestrated endovascular (FEVAR) with open surgical repair (OSR) for treatment of juxtarenal and pararenal aortic aneurysms (J/PAAA). Consecutive patients undergoing elective repair of J/PAAA between 2017 - 2022 in ten high volume centres across five countries were examined. Primary endpoints were midterm mortality and re-intervention. Secondary endpoints included 30 day mortality and re-intervention. Propensity score matching (PSM; 1:1) was performed to adjust for baseline differences. The Strengthening the Reporting of Observational Studies in Epidemiology guidelines were followed. A total of 714 patients were included: 399 (55.9%) FEVAR and 315 (44.1%) OSR. Thirty day mortality (1.5% vs. 1.0%; p = .74) and re-interventions (9.0% vs. 6.3%; p = .21) were similar after FEVAR and OSR. Mean follow up was 26.2 months, without loss to follow up in either group. The 1, 3, and 5 year survival rates were 94.7%, 86.1%, and 71.7% after FEVAR vs. 95.6%, 90.3%, and 86.5% after OSR (p = .042). Re-intervention free survival at 1, 3, and 5 years was lower after FEVAR (89.2%, 81.4%, and 73.3% vs. 98.9%, 97.7%, and 96.3%; p < .001). Similarly, major re-intervention free survival was lower after FEVAR (96.6%, 92.3%, and 91.3% vs. 98.9%, 97.7%, and 96.3% after OSR; p = .045). FEVAR was identified as a predictor of all re-interventions (hazard ratio [HR] 4.40, 95% confidence interval [CI] 1.65 - 11.74; p = .003) but not major re-interventions (HR 2.44, 95% CI 0.98 - 6.04; p = .054) or survival (HR 1.8, 95% CI 0.92 - 3.60; p = .085) on Cox regression analysis. Cox regression analysis of the PSM cohorts confirmed similar results. Both FEVAR and OSR achieved excellent early outcomes for elective J/PAAAs. Although FEVAR was associated with increased overall re-interventions, it was not a predictor of major re-intervention or mortality. In adequately matched patients, overall survival, and freedom from major re-intervention appear comparable between approaches.